螺內酯聯合貝那普利在心力衰竭患者中的應用效果硏究

Study on Application Effect of Spirolactone Combined with Benazepril in Patients with Heart Failure

目的探讨螺内酯联合贝那普利在心力衰竭患者中的临床效果。方法选择2017年6月—2018年8月治疗的心力衰竭患者74例作为对象,电脑抽取随机数法分为对照组(n=37)和观察组(n=37)。对照组给予贝那普利治疗,观察组在对照组基础上联合螺内酯治疗,两组均进行1个月治疗。采用超声心动图测定两组治疗前、治疗后1个月左室收缩末内径、左室舒张末径及左室射血分数;统计并记录两组治疗后恶心呕吐、腹泻、皮疹、血压升高及肝肾功能异常发生率,比较两组临床应用效果。结果观察组治疗后1个月左室收缩末内径(31.37±2.35)mm、左室舒张末径(44.57±3.41)mm水平,低于对照组,差异有统计学意义(t=12.491、9.481,P<0.05);观察组治疗后左室射血分数(57.81±5.77)%,高于对照组,差异有统计学意义(t=3.195,P<0.05);观察组与对照组治疗后并发症发生率为5.41%与对照组10.81%比较差异无统计学意义(χ~2=1.291,P=0.075)。结论将螺内酯联合贝那普利用于心力衰竭患者中有助于改善患者心功能水平,药物安全性较高,值得推广应用。

Objective To study the clinical effect of spirolactone combined with benazepril in patients with heart failure.Methods 74 cases of patients with heart failure treated in our hospital from June 2017 to August 2018 were selected and randomly divided into two groups with 37 cases in each,the control group were treated with benazepril,while the observation group were treated with spirolactone combined with benazepril,and both groups were treated for 1 month,and the left ventricular end systolic diameter,left ventricular end diastolic diameter and left ventricular ejection fraction before treatment and in 1 month after treatment were measured by the echocardiogram,and the vomiting and nausea,diarrhea,rash,elevated blood pressure and liver and kidney dysfunction were counted and recoded after treatment.Results The left ventricular end systolic diameter(31.37±2.35)mm and left ventricular end diastolic diameter(44.57±3.41)mm in 1 month after treatment in the observation group were lower than those in the control group,the difference was statistically significant(t=12.491,9.481,P<0.05);after treatment,the left ventricular ejection fraction(57.81±5.77)%in the observation group was higher than that in the control group,the difference was statistically significant(t=3.195,P<0.05);and the difference in the incidence rate of complications between the observation group and the control group was not statistically significant(5.41%vs 10.81%),the difference wasstatistically significant(χ^2=1.291,P=0.075).Conclusion The spirolactone and benazepril in patients with heart failure can contribute to the cardiac level,with high drug safety,and it is worth promotion and application.